Zermatten A, Cumps J
Acta Psychiatr Belg. 1981 Jul-Aug;81(4):379-98.
The nomifensine antidepressant activity, tolerance and rapidity of action have been studied by 95 psychiatrists in 498 patients during a 4 week open treatment. A 12 items evaluation scale allowed the estimation of the efficacy of the drug in depressed patients distributed to 4 classes of diagnosis: reactional, neurotic, endogenous and other type of depression. Side effects and rapidity of action of the treatment have been recorded during the whole treatment. Nomifensine's antidepressant activity was already observed after one week of treatment: the global scores were significantly diminished at this time in the 4 types of depressive patients. Items such as loss of interest, depressive mood and idea of suicide have been strongly ameliorated and have put in evidence the therapeutic profile and the security of use of this drug The significant and rapid decrease of severity of the symptoms as well as the excellent tolerance of the drug support the psychiatrists' judgement of satisfaction and confirm nomifensine as a major antidepressant, well tolerated and with a rapid onset of action.
95位精神科医生对498例患者进行了为期4周的开放治疗,研究了诺米芬辛的抗抑郁活性、耐受性及起效速度。采用一个包含12个项目的评估量表来评估该药对分为4类诊断(反应性、神经症性、内源性及其他类型抑郁症)的抑郁症患者的疗效。在整个治疗过程中记录了治疗的副作用及起效速度。治疗一周后即已观察到诺米芬辛的抗抑郁活性:此时4类抑郁症患者的总体评分显著降低。诸如兴趣丧失、抑郁情绪及自杀观念等项目得到明显改善,凸显了该药的治疗特点及使用安全性。症状严重程度的显著快速降低以及该药出色的耐受性支持了精神科医生的满意度判断,并证实诺米芬辛是一种主要的抗抑郁药,耐受性良好且起效迅速。